We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > sarilumab

News List

IL-6 antagonists reduce risk of death in hospitalised COVID-19 patients, finds analysis europeanpharmaceuticalreview
July 08, 2021
WHO recommends IL-6 antagonists plus corticosteroids for hospitalised COVID-19 patients based on their ability to reduce risk of death and the need for mechanical ventilation.
Arthritis drugs may reduce mortality and time in ICU for sickest COVID patients worldpharmanews
March 01, 2021
Treating critically ill COVID-19 patients with drugs typically used for rheumatoid arthritis may significantly improve survival, a landmark study has found.
Tocilizumab and sarilumab reduce COVID-19 patient mortality by 8.5 percent, data shows europeanpharmaceuticalreview
January 08, 2021
IL-6 receptor antagonists tocilizumab and sarilumab have a significant impact on COVID-19 patient mortality, a study has shown.
COVID-19 clinical trials exhibit encouraging results: GlobalData expresspharma
May 18, 2020
Four multinational clinical trials that are planning to enrol the most subjects are investigating remdesivir, sarilumab and bevacizumab.